Single-Pot Access to Bisorganoborinates: Applications in Zweifel Olefination
摘要:
Zweifel olefination is a catalyst-free reaction that serves alkene functionalization. While most methods employ commercially available boron pinacol esters, we have assembled a sequence in which the two partners of the formal coupling reaction are installed successively, starting from inexpensive boron alkoxides. The in situ formation of bisorganoborinates was accomplished by consecutive reaction of two different organometallic species. This single-pot procedure represents a great advancement in the generation of organoborinates and their involvement in C-C bond formation.
Iron-Catalyzed <i>E</i>-Selective Dehydrogenative Borylation of Vinylarenes with Pinacolborane
作者:Chao Wang、Caizhi Wu、Shaozhong Ge
DOI:10.1021/acscatal.6b02654
日期:2016.11.4
borylation of vinylarenes with pinacolborane (HBpin) catalyzed by an iron(0) complex “(PMe3)4Fe”. A variety of monosubstituted and disubstituted vinylarenes underwent this iron-catalyzed transformation, affording E-vinyl boronate esters (VBEs) selectively in high yields. In addition, we coupled this iron-catalyzed dehydrogenative borylation with further transformations of the resulting vinyl boronate esters
The present invention provides 1,4 Oxazines of formula I
having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease and type 2 diabetes.
Cyclic sulfones with aminobenzyl substitution useful as BACE inhibitors
申请人:Briard Emmanuelle
公开号:US20100056490A1
公开(公告)日:2010-03-04
The invention relates to novel heterocyclic compounds of the formula
in which all of the variables are as defined in the specification, in free form or in salt form, to their preparation, to their use as medicaments and to medicaments comprising them.
The present invention provides 1,4 Oxazines of formula I
having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease and type 2 diabetes.